Technical Analysis for OTLK - Outlook Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 6.05 | 5.03% | 0.29 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Stochastic Sell Signal | Bearish | 5.03% | |
| NR7 | Range Contraction | 5.03% | |
| NR7-2 | Range Contraction | 5.03% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 19 hours ago |
| 50 DMA Resistance | about 20 hours ago |
| Up 5% | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Upper Bollinger Band Resistance | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/12/2024
Outlook Therapeutics, Inc. Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Ophthalmic Macular Degeneration Specialty Drugs Retina Wet Age Related Macular Degeneration Age Related Macular Degeneration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.8499 |
| 52 Week Low | 4.61 |
| Average Volume | 267,154 |
| 200-Day Moving Average | 7.52 |
| 50-Day Moving Average | 6.05 |
| 20-Day Moving Average | 5.38 |
| 10-Day Moving Average | 5.64 |
| Average True Range | 0.33 |
| RSI (14) | 60.78 |
| ADX | 26.59 |
| +DI | 24.06 |
| -DI | 21.64 |
| Chandelier Exit (Long, 3 ATRs) | 5.10 |
| Chandelier Exit (Short, 3 ATRs) | 5.60 |
| Upper Bollinger Bands | 6.00 |
| Lower Bollinger Band | 4.76 |
| Percent B (%b) | 1.04 |
| BandWidth | 23.15 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.1325 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.46 | ||||
| Resistance 3 (R3) | 6.42 | 6.26 | 6.39 | ||
| Resistance 2 (R2) | 6.26 | 6.15 | 6.27 | 6.36 | |
| Resistance 1 (R1) | 6.15 | 6.09 | 6.21 | 6.19 | 6.34 |
| Pivot Point | 5.99 | 5.99 | 6.01 | 6.00 | 5.99 |
| Support 1 (S1) | 5.88 | 5.88 | 5.94 | 5.92 | 5.76 |
| Support 2 (S2) | 5.72 | 5.82 | 5.73 | 5.74 | |
| Support 3 (S3) | 5.61 | 5.72 | 5.71 | ||
| Support 4 (S4) | 5.65 |
